ArticleInvestigational new drugs2015

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.

Christian Dittrich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.